At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Inotuzumab Ozogamicin as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia
In Brief
A Phase 2 clinical trial evaluating Cyclophosphamide, Cytarabine, and 11 other interventions for Acute Lymphoblastic Leukemia in Remission and 2 related conditions. Terminated early, enrolled 4 participants across 1 site.
Signals
Detailed Summary
This phase II trial studies how well combination chemotherapy and inotuzumab ozogamicin work in treating patients with B acute lymphoblastic leukemia. Drugs used in chemotherapy, such as cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone, methotrexate and cytarabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as inotuzumab ozogamicin, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy and inotuzumab ozogamicin may work better at treating B acute lymphoblastic leukemia.
Study Details
Timeline
Interventions
Given IV
Given IT or IV
Given IV or PO
Given IV
Given IV
Correlative studies
Given IV
Given PO
Given IT, IV or PO
Given IV
Given PO
Given IV
Given IV